Proprietary NCEs & Targets

About Motac Neuroscience

Motac Neuroscience operates a hybrid business model, combining a specialized preclinical CRO service with an internal drug discovery and development pipeline. Its core strength lies in its deep scientific expertise in neurodegenerative and psychiatric disorders, particularly Parkinson's disease, supported by state-of-the-art rodent and non-human primate (NHP) facilities and a team with extensive publication and discovery records. The company leverages its research services to fund and de-risk its own asset development, seeking strategic alliances to advance its proprietary programs targeting movement disorders.

Therapeutic Areas